— Know what they know.
Not Investment Advice

THMO OTC

ThermoGenesis Holdings, Inc.
1W: -0.0% 1M: +0.0% 3M: +0.0% YTD: +0.0% 1Y: +0.0% 3Y: -100.0% 5Y: -100.0%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Devices · Tech Score Neutral · Power 58 · $1585 mcap · 4M float · 0.040% daily turnover · Short 64% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.0001-0.0001
Volume100
Avg Volume1,390
Beta8.03
Dividend—
Analyst Ratings
1 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOXiaochun Xu
Employees25
SectorHealthcare
IndustryMedical - Devices
IPO Date1987-06-05
2711 Citrus Road
Rancho Cordova, CA 95742
US
916 858 5100
About ThermoGenesis Holdings, Inc.

ThermoGenesis Holdings, Inc., founded in 1986 and based in Rancho Cordova, California, is a global innovator specializing in automated systems for cell-banking, cell-processing, and cell-based therapeutic applications. The company's advanced solutions are available across the United States, China, the United Arab Emirates, Vietnam, and other international regions. Its product portfolio encompasses medical devices crucial for automated cell processing. For clinical bio-banking purposes, ThermoGenesis provides the AXP II Automated Cell Separation System, a fully closed system designed for isolating stem and progenitor cells from umbilical cord blood. Complementing this is the BioArchive Automated Cryopreservation System, a robotic, liquid nitrogen-controlled system for both freezing and long-term cryogenic storage of cord blood samples and cell therapeutic products used in clinical environments. In the realm of point-of-care applications, the company offers the XP Point-of-Care System, an automated, sterile, and closed platform that facilitates the rapid processing of autologous stem cells derived from peripheral blood or bone marrow aspirate directly within clinical settings such as surgical centers. Additionally, the PXP-1000 System is another automated, closed solution, engineered for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. For general laboratory use, ThermoGenesis provides its X-Series cell processing products, including X-Lab for cell isolation, the X-Wash System for efficient cell washing and reformulation, and X-Mini for high-efficiency, small-scale cell purification. Beyond its product offerings, the company also delivers contract development and manufacturing (CDMO) services specifically for cell and cell-based gene therapies. Its medical device products are marketed and sold through a network of independent distributors, as well as directly to end-user customers. The company, formerly known as Cesca Therapeutics Inc., officially adopted the name ThermoGenesis Holdings, Inc. in November 2019.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
Xu Xiaochun C-Conversion 0 $0.38 2024-06-28
Xu Xiaochun C-Conversion 0 $0.38 2024-03-15
Xu Xiaochun C-Conversion 4,113,158 $0.38 2024-03-15
Xu Xiaochun S-Sale 600,000 $1.02 2023-11-17
Xu Xiaochun C-Conversion 654,206 $1.07 2023-09-28

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms